Search results
Multiple insiders bought Alkermes plc (NASDAQ:ALKS) stock earlier this year, a positive sign for...
Simply Wall St. via Yahoo Finance· 2 years agoIt is usually uneventful when a single insider buys stock. However, When quite a few insiders buy...
Alkermes (ALKS) Gets Final Award in Janssen Arbitration, Ups View
Zacks via Yahoo Finance· 1 year agoAlkermes ALKS received a final award in its arbitration proceedings with Janssen Pharmaceuticals, a...
Northrop Grumman Leads 5 Defensive Plays Going On Offense; All Are Near Buy Points
Investor's Business Daily· 2 years agoNorthrop Grumman and AutoZone lead this weekend's watch list of five stocks near buy points as...
The 3 Most Undervalued Biotech Stocks to Buy in January
InvestorPlace via Yahoo Finance· 5 months agoCompanies within the biotechnology industry are very interesting to investors because they see wild...
12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
Insider Monkey via Yahoo Finance· 8 months agoIn this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential...
3 Stocks With Momentum Anomaly to Buy on Solid Earnings Rally
Zacks via Yahoo Finance· 2 years agoAlkermes plc (ALKS), BancFirst (BANF) and ExlService (EXLS) are currently witnessing a short-term...
Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
Zacks via Yahoo Finance· 2 years agoPluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating...
11 Most Promising Psychedelic Stocks According to Hedge Funds
Insider Monkey via Yahoo Finance· 6 months agoIn this piece, we will take a look at the 11 most promising psychedelic stocks according to hedge...
LabCorp (LH) Partners HealthVerity to Grow in Drug Development
Zacks via Yahoo Finance· 2 years agoLaboratory Corporation of America Holdings or LabCorp LH continues to remain in the headlines with...
Vascular Biogenics (VBLT) Down, Ovarian Cancer Study Fails
Zacks via Yahoo Finance· 2 years agoVascular Biogenics' (VBLT) phase III OVAL study, evaluating ofra-vec in patients with...